Canadian #Cannabis Stock News: Beleave (CSE:
BE) (CSE: BE.CN) and Dr. Mohit Bhandari Begin Clinical Research Program to
Investigate Therapeutic Use of Cannabinoids for Musculoskeletal Disorders
TORONTO, ON - April 26, 2017 (Investorideas.com Newswire) Beleave
Inc. ("Beleave") (CSE: BE) (CSE: BE.CN) (CNSX: BE) is pleased to
announce that it will begin a clinical research program with Dr. Mohit
Bhandari, to investigate the therapeutic use of cannabinoids for management of
pain in musculoskeletal disorders. In North America, Europe, and Australia,
chronic non-cancer pain is a large contributor to morbidity, affecting as much
as 30% of the population. Musculoskeletal disorders can be triggering events
that lead to the development of chronic pain in up to 40% of chronic pain
cases. Options for pain management in musculoskeletal disorders, both surgical
and non-surgical, remain limited.
Read this news in full at http://www.investorideas.com/news/2017/marijuana/04262BE.asp
Watch the 420 Cannabis Investor video
More Info:
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
No comments:
Post a Comment